๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

1405 POSTER DISCUSSION Cyp2C19*2 Polymorphism Predicts Benefit of Adjuvant Tamoxifen in ER Positive Postmenopausal Breast Cancer Patients

โœ Scribed by K. Beelen; R. Koornstra; M. Opdam; T. Severson; A. Vincent; R.J. van Diest; S. Linn


Book ID
117661391
Publisher
Elsevier Science
Year
2011
Tongue
English
Weight
59 KB
Volume
47
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Genetic polymorphisms of CYP2D6*10 and C
โœ Matthew Goetz; Vera Suman ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 56 KB ๐Ÿ‘ 1 views

The study by Okishiro et al 1 concludes that the cytochrome P450 (CYP) genotype CYP2D6\*10/\*10 is unlikely to have a clinically significant impact on prognosis in women with breast cancer who receive adjuvant tamoxifen. However, several aspects of the study by Okishiro et al call their conclusions